DiaMedica Therapeutics(US:DMAC)2025-05-14 13:00Financial Data and Key Metrics Changes - As of March 31, 2025, the company reported total combined cash and investments of $37.3 million, down from $44.1 million as of December 31, 2024, indicating a decrease due to net cash used to fund operations [10] - Current liabilities decreased to $4.7 million from $5.4 million, while working capital fell to $32.8 million from $39.2 million [10] - Net cash used in operating activities for Q1 2025 was $7.1 million, compared to $6.7 million for Q1 2024, reflecting an increase in net loss [11] Business Line Data and Key Metrics Changes - Research and development expenses increased to $5.7 million for Q1 2025, up from $3.7 million in Q1 2024, primarily due to costs associated with the REMEDY two clinical trial and global expansion [11][12] - General and administrative expenses rose to $2.5 million from $2.1 million, mainly due to additional non-cash share-based compensation [12] Market Data and Key Metrics Changes - The company is currently engaged in two clinical development programs: preeclampsia and stroke, with significant progress reported in both areas [4][8] - Enrollment for the stroke program is progressing steadily, with participant enrollment now between the 20th and 25th percentile mark for the interim analysis [8] Company Strategy and Development Direction - The company aims to advance its clinical development programs, particularly focusing on the preeclampsia program, which is expected to release preliminary top-line results between June and July [5][6] - The company plans to sponsor a preeclampsia key opinion leader call to educate stakeholders on the disease and treatment options [6][7] - Future expansion of the preeclampsia study to the U.S. is planned, with a focus on obtaining results from Part 1a before moving to Parts 1b, 2, and 3 [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in both the preeclampsia and stroke programs, highlighting the importance of upcoming milestones [39] - The company anticipates that its current cash and investments will provide a runway into Q3 2026, indicating a stable financial position for ongoing operations [11] Other Important Information - The company has engaged an experienced stroke neurologist to support site engagement during a key team member's medical leave, ensuring continued enrollment momentum [8] Q&A Session Summary Question: Clarification on laboratory test results timing - Management confirmed that the main variable affecting the timing of results is the placental transfer assay, which is being finalized [15][16] Question: Triggers for advancing to Part 2 and 3 of the preeclampsia study - Management indicated that dilation of intrauterine arteries would trigger movement to the fetal growth restriction cohort [17][18] Question: Anticipated read-through from preeclampsia data to stroke development - Management noted that positive preeclampsia data would confirm the activity of the protein being studied, which is also used in stroke treatment [22][24] Question: Update on stroke program enrollment and high-volume centers - Management reported that some high-enrolling sites are achieving one to two patients per month, with overall enrollment momentum building [26][28] Question: Future expansion of the preeclampsia study to the U.S. - Management confirmed plans to expand the study to the U.S. in the future, contingent on results from the current phases [34][36]